Search results for " prostate"

showing 10 items of 177 documents

Primary Radical Prostatectomy or Ablative Radiotherapy as Protective Factors for Patients With mCRPC Treated With Radium-223 Dichloride: An Italian M…

2020

Abstract Background We investigated, in a real-life setting, the prognostic relevance of previous primary treatment (radical prostatectomy [RP] or external beam radiotherapy [EBRT]) on overall survival for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra). Materials and Methods In the present multicenter retrospective study, we enrolled 275 consecutive patients. The demographic and clinical data and mCRPC characteristics were recorded and evaluated at baseline and at the end of treatment or progression. 223Ra was administered according to the current label authorization until disease progression or unacceptable toxicity. We divided the who…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentoverall survivalBrachytherapy030232 urology & nephrologyUrology223-ra03 medical and health sciencesProstate cancer0302 clinical medicineAblative casemedicineHumansExternal beam radiotherapyradiotherapyAgedRetrospective StudiesAged 80 and overProstatectomyRadioisotopesbusiness.industryProstatectomyRetrospective cohort studymCRPCMiddle AgedProtective Factorsmedicine.diseasePrognosisCombined Modality TherapyRadiation therapySurvival RateProstatic Neoplasms Castration-ResistantOncologyMulticenter study223-ra; mCRPC; prostatectomy; radiotherapy; overall survivalItaly030220 oncology & carcinogenesisCohortDisease ProgressionbusinessSettore SECS-S/01Follow-Up StudiesRadium
researchProduct

Model‐based meta‐analysis of the time to first acute urinary retention or benign prostatic hyperplasia‐related surgery in patients with moderate or s…

2021

Aims Combination therapy of 5α‐reductase inhibitor and α‐blocker is a guideline‐endorsed therapeutic approach for patients with moderate‐to‐severe lower urinary tract symptoms or benign prostatic hyperplasia (LUTS/BPH) who are at risk of disease progression. We aimed to disentangle the contribution of clinical and demographic baseline characteristics affecting the risk of acute urinary retention or BPH‐related surgery (AUR/S) from the effect of treatment with drugs showing symptomatic and disease‐modifying properties. Methods A time‐to‐event model was developed using pooled data from patients (n = 10 238) enrolled into six clinical studies receiving placebo, tamsulosin, dutasteride or tamsu…

Malemedicine.medical_specialtydisease‐modifying propertiesCombination therapyProstatic HyperplasiaPlacebo030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicinebaseline risk factorsLower urinary tract symptomsTamsulosinHumansMedicinePharmacology (medical)lower urinary tract symptoms030212 general & internal medicineacute urinary retentionPharmacologybenign prostatic hyperplasiadutasterideSulfonamidesbusiness.industryUrinary retentionHazard ratioOriginal ArticlesUrinary Retentionmedicine.diseaseDutasterideSurgeryTreatment OutcomechemistryAzasteroidstamsulosinOriginal ArticleDrug Therapy CombinationInternational Prostate Symptom Scoremedicine.symptombusinesstime‐to‐event modellingmedicine.drugBritish Journal of Clinical Pharmacology
researchProduct

Prediction by quantitative histology of pathological stage in prostate cancer.

2005

To find a predictor of extraprostatic extension in clinically localized prostate cancer (PCa), pre-operative ultrasound-guided prostate needle biopsies and clinico-pathological data were reviewed.One hundred and eighty-three consecutive patients who underwent radical retropubic prostatectomy for clinical T1-T2 PCa and serum PSA10 ng/ml were reviewed. Pre-operative biopsy was performed according to an extended protocol and whole-mount prostatectomy specimens were processed. The following biopsy variables were categorized to this analysis: Gleason score (or =6,6), TPC (or =20%;20%), GPC (or =50%;50%), cancer-positive cores (or =2;2), cancer-positive cores in both lateral portions (yes; no), P…

Malemedicine.medical_specialtymedicine.medical_treatmentBiopsyUrologyurologic and male genital diseasesLogistic regressionSensitivity and SpecificityProstate cancerProstatePredictive Value of TestsBiopsymedicineOdds RatioHumansStage (cooking)AgedNeoplasm Stagingmedicine.diagnostic_testbusiness.industryProstatic NeoplasmsGeneral MedicineOdds ratioMiddle AgedProstate-Specific Antigenmedicine.diseaseSurgerymedicine.anatomical_structureLogistic ModelsOncologyROC CurveMultivariate AnalysisSurgeryPositive Surgical MarginbusinessRadical retropubic prostatectomyEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature.

2014

The intrinsic physical and radiobiological characteristics of High Dose Rate Brachytherapy (HDR-BT) are well suited to the treatment of prostate cancer. HDR-BT was initially used as a boost to external beam brachytherapy, but has subsequently been employed as the sole treatment, which is termed HDR monotherapy. This review summarizes the clinical outcomes and toxicity results of the principal studies and discusses the radiobiological basis supporting its use.

Malemedicine.medical_specialtymedicine.medical_treatmentBrachytherapyBrachytherapyProstate cancermedicineEffective treatmentHumansMedical physicsDose FractionationSalvage brachytherapySalvage TherapyProstate cancerbusiness.industryRadiobiologyProstatic NeoplasmsRadiotherapy DosageHDR-BTHematologymedicine.diseaseBrachytherapy boost; HDR-BT; High-dose rate brachytherapy; Prostate cancer; Radiobiology; Salvage brachytherapy; Dose Fractionation; Humans; Male; Prostatic Neoplasms; Salvage Therapy; Treatment Outcome; Brachytherapy; Radiotherapy Dosage; Hematology; Oncology; Geriatrics and GerontologyHigh-Dose Rate BrachytherapyBrachytherapy boostTreatment OutcomeOncologyRadiologyDose Fractionation RadiationGeriatrics and GerontologybusinessHigh-dose rate brachytherapySalvage brachytherapyCritical reviews in oncology/hematology
researchProduct

Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment

2019

Background: Active surveillance (AS) has been increasingly proposed as the preferential initial management strategy for low-risk prostate cancer (PC), while in high-risk PC the indication for surgery has widened. Objective: To evaluate the development of risk group distribution of patients undergoing radical prostatectomy (RP). Design, setting, and participants: Retrospective database review of combined RP databases (2000-2015) of four large European centers (Créteil, Paris; San Rafaele, Milan; Martini Klinik, Hamburg; NKI, AvL, Amsterdam). Outcome measurements and statistical analysis: Clinical and pathological characteristics per year of surgery. Eligibility for AS was defined according …

Malemedicine.medical_specialtymedicine.medical_treatmentUrology030232 urology & nephrologyRisk classificationDiseaseActive surveillanceRisk AssessmentTreatment trend03 medical and health sciencesProstate cancer0302 clinical medicineRisk groupsInternal medicineHumansMedicineDistribution (pharmacology)Watchful WaitingPathologicalRetrospective StudiesProstatectomyProstate cancerbusiness.industryProstatectomyProstatic NeoplasmsCancerProstate-Specific Antigenmedicine.diseaseTailored treatmentRadical prostatectomySurgeryEurope030220 oncology & carcinogenesisNeoplasm Gradingbusiness
researchProduct

Predicting trajectories of recovery in prostate cancer patients undergone Robot-Assisted Radical Prostatectomy (RARP)

2019

ObjectiveTo identify trends of patients' urinary and sexual dysfunctions from a clinical and psychological perspective and understand whether sociodemographic and medical predictors could differentiate among patients following different one-year longitudinal trajectories.MethodsAn Italian sample of 478 prostate cancer patients undergone Robot-Assisted Radical Prostatectomy completed the EPIC-26 survey between July 2015 and July 2016 at the pre-hospitalization (T0), 45 days (T1) and 3 (T2), 6 (T3), 9 (T4), and 12 months (T5) after surgery. Sociodemographic and clinical characteristics (age, BMI, diabetes, nerve-sparing procedure) were also collected. Latent Class Growth Analysis was conducte…

Malemedicine.medical_treatmentCancer Treatment030232 urology & nephrologyUrinary incontinenceProstate cancerPostoperative ComplicationsEndocrinology0302 clinical medicineErectile DysfunctionRobotic Surgical ProceduresQuality of lifeMedicine and Health SciencesrecoveyReproductive System ProceduresMultidisciplinaryProstatectomyProstate CancerQProstate DiseasesRRadical ProstatectomyTreatment OutcomeItalyOncology030220 oncology & carcinogenesisMedicinemedicine.symptomResearch Articlemedicine.medical_specialtySexual DysfunctionEndocrine DisordersUrologyScienceUrinary systemSurgical and Invasive Medical ProceduresAffect (psychology)03 medical and health sciencesDiabetes MellitusmedicineHumansProstatectomyIncontinenceSurgical ExcisionGeriatric Urologybusiness.industryCancers and Neoplasmsmedicine.diseaseGenitourinary Tract TumorsUrinary IncontinenceSexual dysfunctionSocioeconomic FactorsGeriatricsMetabolic DisordersQuality of LifePhysical therapybusinessSexual functionPLOS ONE
researchProduct

Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resi…

2018

In vivo pharmacokinetic analysis of [Sc]Sc-PSMA-617 was used to determine the normal organ-absorbed doses that may result from therapeutic activity of [Lu]Lu-PSMA-617 and to predict the maximum permissible activity of [Lu]Lu-PSMA-617 for patients with metastatic castration-resistant prostate carcinoma. Methods Pharmacokinetics of [Sc]Sc-PSMA-617 was evaluated in 5 patients with metastatic castration-resistant prostate carcinoma using dynamic PET/CT, followed by 3 static PET/CT acquisitions and blood sample collection over 19.5 hours, as well as urine sample collection at 2 time points. Total activity measured in source organs by PET imaging, as well as counts per milliliter measured in bloo…

Malemedicine.medical_treatmentUrineLutetiumRadiation Dosageurologic and male genital diseases030218 nuclear medicine & medical imagingCastration-Resistant Prostate CarcinomaHeterocyclic Compounds 1-Ring03 medical and health sciences0302 clinical medicinePharmacokineticsIn vivoPositron Emission Tomography Computed TomographyOrganometallic CompoundsmedicineHumansRadiology Nuclear Medicine and imagingExternal beam radiotherapyNeoplasm MetastasisAgedUrinary bladderbusiness.industryRadiotherapy Planning Computer-AssistedCarcinomaRadiotherapy DosageDipeptidesGeneral MedicineProstate-Specific AntigenProstatic Neoplasms Castration-Resistantmedicine.anatomical_structure030220 oncology & carcinogenesisSample collectionBone marrowRadiopharmaceuticalsbusinessNuclear medicineScandiumClinical Nuclear Medicine
researchProduct

Role of abdominal obesity for functional outcomes and complications in men treated with radical prostatectomy for prostate cancer: results of the Mul…

2014

Objective. This study aimed to evaluate the impact of abdominal obesity on preoperative features, complications and functional outcomes of men treated with radical prostatectomy (RP) for prostate cancer. Material and methods. In 2006 a multicentre Italian report on RP evaluated the surgical and functional characteristics of prostate cancer and RP outcomes. Age and waist circumference (WC) were recorded. Abdominal obesity was defined as a WC of at least 102 cm. International Index of Erectile Function (IIEF) score, prostate-specific antigen, prostate volume, tumour characteristics, presence/absence of perioperative complications and the number of blood units transfused were recorded. Preoper…

Maleobesitymedicine.medical_treatmentLogistic regressionsurgeryProstate cancerPostoperative ComplicationsErectile DysfunctionProstateProspective StudiesProspective cohort studyAbdominal obesityProstatectomyMiddle Agedprostate cancerTreatment Outcomemedicine.anatomical_structureItalyNephrologyObesity AbdominalabdominalepidemiologyWaist Circumferencemedicine.symptomHumanmedicine.medical_specialtyWaistcomplicationsUrologyUrologymethodsabdominal obesityincontinenceepidemiology/etiologymedicineHumansAgedProstatectomybusiness.industryfunctional outcomes and complicationProstatic Neoplasmsmethods; abdominal; prospective studies; erectile dysfunction; male; obesity; epidemiology; middle aged; treatment outcome; humans; prostatic neoplasms; epidemiology/etiology; surgery; aged; incontinence; complications; waist circumference; prostatectomy; postoperative complications; prostate cancer; urinary incontinence; italyPerioperativemedicine.diseaseradical prostatectomyMIRRORProspective StudieUrinary IncontinenceProstatic NeoplasmPostoperative ComplicationbusinessComplicationScandinavian Journal of Urology
researchProduct

Nanostructured Lipid Carriers-Containing Anticancer Compounds: Preparation, Characterization, and Cytotoxicity Studies

2007

This article describes the development of nanostructured lipid carriers (NLC) as colloidal carriers for two antitumor compounds that possess a remarkable antineoplastic activity. But their limited stability and low solubility in water could give a very low parenteral bioavailability. Results revealed an enhancement of the cytotoxicity effect of drug-loaded NLC on human prostate cancer (PC-3) and human hepatocellular carcinoma (HuH-6, HuH-7) cell lines with respect to that of both free drugs. Results of characterization studies strongly support the potential application of these drugs-loaded NLC as prolonged delivery systems for lipophilic drugs by several administration routes, in particula…

Materials scienceCell SurvivalDrug CompoundingPharmaceutical ScienceNanoparticleAntineoplastic AgentsPharmacologynanostructured lipid carrierHuman prostatehuman prostate carcinoma cellPlasmaCell Line TumorElectrochemistryHumansParticle SizeSolubilityCytotoxicityChromatography High Pressure LiquidDrug CarriersGeneral Medicineantitumor drugLipidsControlled releaseBioavailabilitySolubilityPlasma chemistryNanoparticleshuman hepatocellular carcinoma cellcontrolled releaseDrug metabolism
researchProduct

VISCERAL FAT TISSUE ACTIVITY DOES NOT CORRELATE TO HIGH GRADE PROSTATE CANCER RISK AT BIOPSY

2015

Metabolic syndrome visceral fat prostate cancer leptinSettore MED/24 - Urologia
researchProduct